Advanced Oncotherapy Regulatory News (AVO)



Advanced Oncotherapy plc

("AVO" or the "Company")

Exercise of Warrants

Advanced Oncotherapy (AIM: AVO), the developer of innovative medical technology for cancer treatment, announces that it has issued 5,750,000 new AVO ordinary shares ("Ordinary Shares") at a subscription price of 3.4559 pence each (adjusted since the figure announced in August as a result of the recently completed fundraising) to Darwin Strategic Ltd, who has exercised warrants issued in August 2014 in connection with finance facilities provided to the Company which have been repaid. Darwin Strategic Ltd holds warrants over a further 2,514,463 Ordinary Shares.

 Application has been made for the 5,750,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will occur on or about 29 September 2014. The new Ordinary Shares will rank pari passu in all aspects with the existing Ordinary Shares of the Company.

 Total Voting Rights

Following Admission, the Company's enlarged issued share capital will comprise 1,020,853,424 Ordinary Shares, with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of Ordinary Shares in the Company with voting rights will be 1,020,853,424. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

Contacts: